# HDAC Inhibitor Augmentation to Clozapine

> **NCT03263533** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Virginia Commonwealth University**

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Vorinostat Oral Capsule Group 1
- **DRUG:** Vorinostat Oral Capsule Group 2

## Key facts

- **NCT ID:** NCT03263533
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-04
- **Primary completion:** 2019-02
- **Final completion:** 2019-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PIs were unable to recruit any participants
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263533, "HDAC Inhibitor Augmentation to Clozapine". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03263533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*